QT dispersion in patients with chronic heart failure: β blockers are associated with a reduction in QT dispersion

C E Bonnar, A P Davie, L Caruana, L Fenn, S A Ogston, J J V McMurray, A D Struthers

Abstract

Objective—To compare QT dispersion in patients with impaired left ventricular systolic function and in matched control patients with normal left ventricular systolic function.

Design—A retrospective, case-control study with controls matched 4:1 for age, sex, previous myocardial infarction, and diuretic and β blocker treatment.

Setting—A regional cardiology centre and a university teaching hospital.

Patients—25 patients with impaired left ventricular systolic function and 100 patients with normal left ventricular systolic function.

Main outcome measures—QT and QTc dispersion measured by three methods: the difference between maximum and minimum QT and QTc intervals, the standard deviation of QT and QTc intervals, and the “lead adjusted” QT and QTc dispersion.

Results—All measures of QT/QTc dispersion were closely interrelated (r values 0.86 to 0.99; all p < 0.001). All measures of QT and QTc dispersion were significantly increased in the patients with impaired left ventricular systolic function vs controls (p < 0.001): 71.9 (6.5) (mean (SEM)) vs 46.9 (1.7) ms for QT dispersion, and 83.6 (7.6) vs 54.3 (2.1) ms⁻¹ for QTc dispersion. All six dispersion parameters were reduced in patients taking β blockers (p < 0.05), regardless of whether left ventricular function was normal or impaired—by 9.4 (4.6) ms for QT dispersion (p < 0.05) and by 13.8 (6.5) ms⁻¹ for QTc dispersion (p = 0.01).

Conclusions—QT and QTc dispersion are increased in patients with systolic heart failure in comparison with matched controls, regardless of the method of measurement and independently of possible confounding factors. β Blockers are associated with a reduction in both QT and QTc dispersion, raising the possibility that a reduction in dispersion of ventricular repolarisation may be an important antiarrhythmic mechanism of β blockade. (Heart 1999; 81:297–302)

Keywords: QT dispersion; heart failure; β blockers; sudden death

Clinical and experimental electrophysiological studies have shown the importance of inhomogeneous myocardial repolarisation in the genesis of ventricular arrhythmias. Increased dispersion of repolarisation provides a substrate for ventricular arrhythmias by generating areas of functional unidirectional block, thereby predisposing to reentry. QT dispersion, defined as the difference between the longest and the shortest QT interval on the surface ECG, is a validated measure of dispersion of repolarisation.QT dispersion predicts sudden death and ventricular arrhythmias in patients with chronic heart failure from coronary heart disease and in hypertrophic obstructive cardiomyopathy. QT dispersion also predicts cardiac death in patients with hypertension and peripheral vascular disease.

In patients with chronic heart failure from idiopathic dilated cardiomyopathy, QT dispersion has no predictive value for sudden death or ventricular arrhythmias and there have been conflicting reports of its prognostic value in patients with acute myocardial infarction.

There are few controlled studies of whether QT dispersion is abnormal in chronic heart failure. Two studies in patients with heart failure from coronary heart disease reported conflicting findings—QT dispersion was not increased in one but was increased in the other. In the latter study, however, 60% of patients had a previous myocardial infarct, a clinical event thought to increase QT dispersion even in the presence of preserved left ventricular systolic function. Two other studies in patients with chronic heart failure caused by idiopathic dilated cardiomyopathy showed increased QT dispersion. However, both of these studies, like the previous two, used healthy controls, which is less than ideal because they are not matched for the possible effects of drugs, diuretic induced electrolyte abnormalities, or sex imbalance.

The aim of our study was therefore to compare the QT dispersion of a group of patients with impaired left ventricular systolic function with a large number of control patients who had normal systolic function but were matched for other confounding variables such as age, sex, diuretic and β blocker treatment, and previous myocardial infarction. To perform such a matched study, we chose a unique population of relatively unselected, breathless, diuretic treated patients referred because of suspected heart failure for echocardiography. Some of these patients did and some did not have left ventricular systolic dysfunction.
Methods

Patients with suspected heart failure were studied at the open access echocardiography service at the Western General Hospital, Edinburgh, which has been described previously. Briefly, current symptoms, past medical history, conventional risk factors, and current cardiovascular drugs by class were recorded for each patient. All patients had ECG records made at the same paper speed and gain setting (25 mm/ms and 10 mm/mV, respectively). Full cross sectional, M mode, colour flow, and Doppler echocardiographic studies were then performed by an experienced technician and reported by a cardiologist. Left ventricular systolic function was quantified in terms of fractional shortening and was considered to be significantly impaired if it was less than 25% in the absence of valvar regurgitation. In non-echogenic subjects, a semiquantitative assessment of left ventricular systolic function was made, being either normal or impaired.

PATIENT GROUPS

From the first 534 patients referred to the open access service, 96 had significantly impaired left ventricular systolic function and 438 had preserved left ventricular systolic function. Patients were excluded from the analysis if they had any of the following: atrial fibrillation, atrial flutter, right or left bundle branch block (BBB), electrocardiographic left ventricular hypertrophy (ECG-LVH), or hypertension. QT dispersion is significantly increased in patients with hypertension, correlating with systolic blood pressure and left ventricular mass index, so we wished to avoid this possible confounding influence.

Of the 96 patients with impaired left ventricular systolic function, 38 had one of the exclusion criteria (atrial fibrillation 6, BBB 14, ECG-LVH 12, hypertension 6) and 29 patients had two or more exclusion criteria. In the remaining 29 patients, QT dispersion could not be measured in four cases because of frequent ventricular ectopic beats (2) or poor quality ECG recordings (2), leaving 25 patients with impaired left ventricular systolic function. Of the 438 patients with preserved left ventricular systolic function, 171 had one of the exclusion criteria (atrial fibrillation 18, atrial flutter 2, BBB 21, ECG-LVH 22, hypertension 108) and 65 had two or more exclusion criteria, leaving 202 patients. The 25 patients with impaired left ventricular systolic function were then matched as closely as possible for beta blocker treatment, diuretic treatment (loop, thiazide, or combination), sex, age, and previous myocardial infarction with 100 of the 202 patients with preserved left ventricular systolic function. We then compared QT and QTc dispersion in each of these groups.

QT DISPERSION

All ECGs were digitised by a single observer, blinded to the assigned group of each patient. ECGs were digitised manually with the aid of a digitising tablet connected to a personal computer. The QT interval was measured from the beginning of the QRS complex to the end of the T wave, defined as the return to T-P baseline. When U waves were present, the QT interval was measured to the nadir of the curve between the T and U waves. QT intervals were measured in all leads if possible. The QT interval could be measured in at least seven leads in all patients in the study. For each lead, two or three consecutive cycles were measured and the arithmetic mean of the QT interval for that lead was used in all future calculations for QT dispersion.

We measured QT dispersion in three different ways. First, QT dispersion was defined as the difference between the maximum and minimum measured QT intervals across the 12 lead ECG. This is entirely dependent on the values observed in just two of the 12 leads and is markedly influenced by the number of leads in which the QT interval can be properly measured. Second, we measured the standard deviation of all QT intervals in each ECG (SD-QT interval). This incorporates information from all measured leads, not just maximum and minimum values; of all the formulas used for QT dispersion it is the least affected by using different numbers of leads in different patients. Third, “adjusted” QT dispersion is QT dispersion divided by the square root of the number of leads in which the QT interval was measured, a formula proposed by Day et al to compensate for using different numbers of leads in different patients. All three formulas were then expressed as both “uncorrected” QT dispersion and “rate corrected” QTc dispersion, using Bazett’s formula.

STATISTICAL ANALYSIS

Statistical tests were performed using a dedicated software package (SPSS version 7.5 for Windows-NT); χ² analysis was used to compare differences in the baseline characteristics in the groups, and simple linear regression to test for associations between variables. For between group comparisons, one way analysis of variance (ANOVA) and multiple regression analysis were used. A p value < 0.05 was considered to be significant. Values throughout the text and in the tables are expressed as mean (SEM).

Results

PATIENT CHARACTERISTICS

Table 1 outlines the baseline characteristics for each group of patients and shows that the groups were well balanced. We were unable to match precisely for previous myocardial infarction or diabetes, both of which were more common in the chronic heart failure group (p < 0.05). These imbalances were taken into account in the multiple regression analysis, which adjusted for any possible increase in QT/QTc dispersion indices in the chronic heart failure group caused by these differences. In addition, seven patients with impaired left ventricular systolic function were taking calcium antagonists, seven were taking long acting nitrates, four were taking angiotensin converting enzyme (ACE) inhibitors, and three were taking digoxin. Of the 100 patients with preserved left ventricular systolic function, 15
Table 1 QT and QTc dispersion in patients with impaired left ventricular systolic function and matched controls with preserved left ventricular systolic function

<table>
<thead>
<tr>
<th>Impaired ventricular function</th>
<th>Preserved</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Number of patients</td>
<td>25</td>
<td>100</td>
</tr>
<tr>
<td>Age (years)</td>
<td>69.2 (2.1)</td>
<td>67.7 (1.5)</td>
</tr>
<tr>
<td>Male (% (n))</td>
<td>48% (12/25)</td>
<td>49% (49/100)</td>
</tr>
<tr>
<td>Diuretics (% (n))</td>
<td>68% (17/25)</td>
<td>63% (63/100)</td>
</tr>
<tr>
<td>β Blockers (% (n))</td>
<td>16% (4/25)</td>
<td>13% (13/100)</td>
</tr>
<tr>
<td>Diabetes mellitus (type I or II) (% (n))</td>
<td>24% (6/25)</td>
<td>3% (3/100)</td>
</tr>
<tr>
<td>Previous history of MI (% (n))</td>
<td>52% (13/25)</td>
<td>23% (23/100)</td>
</tr>
<tr>
<td>QT dispersion (ms)</td>
<td>71.9 (5.6)</td>
<td>46.9 (1.7)</td>
</tr>
<tr>
<td>QTc dispersion (ms)</td>
<td>83.6 (7.6)</td>
<td>54.3 (2.1)</td>
</tr>
<tr>
<td>SD-QT interval (ms)</td>
<td>24.4 (2.6)</td>
<td>14.8 (0.5)</td>
</tr>
<tr>
<td>SD-QTc interval (ms)</td>
<td>28.1 (3.0)</td>
<td>17.3 (0.7)</td>
</tr>
<tr>
<td>Ad. QT dispersion (ms)</td>
<td>22.9 (2.1)</td>
<td>14.7 (0.5)</td>
</tr>
<tr>
<td>Ad. QTc dispersion (ms−1)</td>
<td>26.7 (2.4)</td>
<td>17.0 (0.7)</td>
</tr>
</tbody>
</table>

Values are mean (SEM) unless otherwise stated; χ² analysis except; †Student's t test; *analysis of variance.

Ad. QT dispersion, “lead adjusted” QT dispersion; Ad. QTc dispersion, “lead adjusted” QTc dispersion; MI, myocardial infarction; QT dispersion, QT dispersion corrected for heart rate using Bazett's formula; SD-QT interval, standard deviation of the QT interval; SD-QTc interval, standard deviation of the QTc interval.

Table 2 QT and QTc dispersion in patients not taking and taking chronic β blocker treatment

<table>
<thead>
<tr>
<th>Chronic β blocker treatment</th>
<th>No</th>
<th>Yes</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>108</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>QT dispersion (ms)</td>
<td>53.2 (1.9)</td>
<td>43.8 (4.9)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>QTc dispersion (ms)</td>
<td>62.0 (2.4)</td>
<td>48.2 (6.1)</td>
<td>0.01</td>
</tr>
<tr>
<td>SD-QT interval (ms)</td>
<td>17.1 (0.7)</td>
<td>14.2 (1.7)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>SD-QTc interval (ms)</td>
<td>20.1 (0.9)</td>
<td>15.6 (2.2)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Ad. QT dispersion (ms)</td>
<td>16.8 (0.6)</td>
<td>13.7 (1.5)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Ad. QTc dispersion (ms−1)</td>
<td>19.6 (0.8)</td>
<td>15.0 (1.9)</td>
<td>&lt; 0.01</td>
</tr>
</tbody>
</table>

*Analysis of variance adjusted for the factors and covariates in the multiple regression.

Ad. QT dispersion, “lead adjusted” QT dispersion; Ad. QTc dispersion, “lead adjusted” QTc dispersion; SD-QT interval, standard deviation of QT interval; SD-QTc interval, standard deviation of the rate corrected QT interval.

Discussion

We have shown for the first time that QT dispersion is increased in patients with chronic heart failure compared with matched controls. Previous studies of QT dispersion in patients with chronic heart failure have tended to compare healthy controls with patients with a past history of myocardial infarction and who are receiving pharmacological treatment. It has therefore previously been impossible to determine whether abnormal QT dispersion in these patients was caused by left ventricular dysfunction, previous infarction, or drug treatment. Our findings show that QT dispersion is increased in patients with systolic heart failure compared with appropriately matched breathless patients without systolic heart failure. Our finding that four of the six measures of QT/QTc dispersion were not significantly increased in patients with a previous myocardial infarct suggests that it is the left ventricular dysfunction per se rather than the previous infarction that leads to abnormal QT dispersion. Furthermore, we found that digoxin treatment increased four of the six QT/QTc dispersion indices and that chronic diuretic treatment was not associated with any effect on QT dispersion.
One interesting finding that emerged from this analysis was that chronic β blocker treatment is associated with reduced QT and QTc dispersion, regardless of whether left ventricular function was preserved or impaired. This was observed in 16 of the 17 patients in the study who were taking β blockers (one patient with a surgically repaired ventricular aneurysm had increased QT dispersion despite β blockade, presumably as a result of distorted ventricular anatomy). It is unlikely that the effect we observed is an anti-ischaemic one, since nitrates and calcium antagonists (which were used by more of the patients than were β blockers) were not associated with any index of QT or QTc dispersion.

Little is known about the aetiology of increased QT dispersion in patients with chronic heart failure, but sympathetic tone, excitation–contraction coupling, and myocardial fibrosis may all be important. Sympathetic tone is greatly increased in patients with chronic heart failure compared to controls, as shown by studies of plasma and urinary catecholamines, noradrenaline spillover techniques, and heart rate variability, and this occurs even in patients with mild or asymptomatic chronic heart failure. Angiotensin II in particular exerts a marked stimulatory effect on central sympathetic modulation, noradrenaline secretion from sympathetic nerve terminals, and adrenergic receptor responsiveness.

Chronic ACE inhibitor treatment in patients with chronic heart failure is associated with a reduction in plasma noradrenaline and muscle sympathetic nerve traffic (implying sympathetic deactivation), and we have previously shown that six weeks of treatment with enalapril in patients with mild asymptomatic chronic heart failure reduces QT dispersion. This, together with our present finding that QT dispersion is lower in patients taking chronic β blocker treatment, suggests that sympathetic activation may be an important cause of increased QT dispersion in patients with chronic heart failure (the fact that ACE inhibitors did not reduce QT dispersion in this study was probably due to the small numbers of patients taking them).

Three other pieces of evidence support this theory. First, we have recently shown that QT dispersion significantly increases at dawn in patients with chronic heart failure, in parallel with the dawn surge in sympathetic activity. Second, we have also recently shown that QT dispersion correlates significantly with the low frequency component of heart rate variability (expressed in normalised units), which is an accepted measure of sympathetic nervous system activity. Third, intravenous and intracoronary salbutamol increase QT dispersion in patients with coronary artery disease. Finally, it is worth pointing out that in one of the earliest studies investigating dispersion of ventricular repolarisation, Han and Moe showed that sympathetic activation increases dispersion of refractoriness and reduces ventricular fibrillation threshold.

There are other possible reasons why QT dispersion is increased in patients with chronic heart failure. All types of heart failure, regardless of aetiology, are associated with changes in left ventricular size, function, or pressure, each of which may exert important electrophysiological effects (excitation–contraction coupling), including an increase in the dispersion of ventricular repolarisation. Previous studies, however, have reported weak correlations between QT dispersion and indices of left ventricular size or function in patients with chronic heart failure. Myocardial fibrosis has also been proposed as a cause of increased QT dispersion in patients with chronic heart failure, mainly because of the finding that patients with diffuse coronary artery disease have considerably greater QT dispersion than patients with one, two, or three vessel disease.

In patients with idiopathic long QT syndrome, Priori et al showed that those responding to β blocker treatment had significantly reduced QT dispersion compared with non-responders. As in our study, this suggested but did not prove that β blockers reduce QT dispersion. It is also worth pointing out that complete removal of β adrenergic activity by left cardiac sympathetic denervation in the study by Priori et al significantly reduced QT dispersion as well. Sotalol reduces QTc dispersion in patients after acute myocardial infarction but this effect has been attributed to its class III and not to its class II properties.

Our findings suggest that β blockers may independently reduce both QT and QTc dispersion, which could be of considerable significance in explaining their ability to prevent ventricular arrhythmias and sudden cardiac death after acute myocardial infarction. Although many mechanisms of action have been proposed to explain the beneficial effects of β blockers, the precise antiarrhythmic mechanism has not yet been identified. The traditional view has arisen that the effects of β blockers on cardiac repolarisation are not of crucial significance in mediating their antiarrhythmic effects, although few studies have specifically examined whether chronic β blockade actually influences ventricular repolarisation. The available studies do suggest an effect, since monophasic action potential duration, ventricular effective refractory periods, and QT intervals all increase with chronic β blocker treatment. Fewer studies still have examined whether chronic β blockade influences the dispersion of ventricular repolarisation, presumably because this was used to be so difficult to measure by invasive endocardial catheter mapping or cumbersome body surface mapping. With the advent of QT dispersion, this has become much easier, albeit more indirect. Our study, and that of Priori et al, suggests that an important additional antiarrhythmic property of chronic β blockade may be the ability to reduce increased dispersion of ventricular repolarisation, an important precursor of re-entry.

As in the majority of studies of QT dispersion all QT intervals in our study were measured manually, with the aid of a digitiser. There is evidence that manual measurement is superior to automatic measurement of QT dis-
QT dispersion in patients with chronic heart failure

In summary, we found that QT dispersion measured by several methods is increased in patients with systolic heart failure compared with appropriately matched breathless patients without systolic heart failure. Our findings suggest that it is the presence of left ventricular systolic dysfunction per se and not a previous myocardial infarct that increases QT dispersion in patients with chronic heart failure. Our study was a retrospective observational study and as such has several well known limitations. The patients in the study were generally not taking ACE inhibitors and so are representative of chronic heart failure failure patients as they present, rather than when they are optimally treated. In addition, we had no information on electrolytes in any of our patients but by controlling for diuretic treatment, we hoped to control for hypokalaemia and hypomagnesaemia, both of which have been shown to increase QT dispersion.

Also, we had no information on the final diagnoses of patients referred with suspected heart failure who were subsequently shown to have normal left ventricular systolic function. Likely causes of breathlessness in these patients—such as chronic obstructive pulmonary disease (COPD)—may have influenced QT dispersion. However, QT dispersion in patients with COPD is increased compared with controls, and this would have been expected to reduce and not increase the difference we observed between the two study groups.

CONCLUSION

The fact that our controls were not normal, healthy patients—in the sense that the majority had symptoms leading to a suspicion of heart failure—is not a limitation of our study but an overall advantage, since our control group was ideal in that they could be matched to our patients for nearly all confounding variables.

LIMITATIONS


Bonnar CE, Gillespie ND, MacFadyen RJ, et al. QT dispersion is significantly increased between 6 am and 8 am in unstable chronic heart failure patients—A possible role in sudden death? [abstract] Am Coll Cardiol 1997;29(Suppl A):510A.


Singh BN, Courtney KR. The classification of arrhythmogenic mechanisms of drug action: experimental and clinical
Biatrial thrombosis in cardiac amyloidosis

A 60 year old woman was admitted to hospital because of congestive heart failure. Primary AL amyloidosis with extensive infiltration of the heart was diagnosed. The ECG showed sinus rhythm and low QRS voltage.

Transthoracic echocardiography typically documented a diffuse thickening of atrial and ventricular walls, preserved systolic ventricular function, and dilatation of the atria. In the body of left atrium a small thrombus was visible.

Transoesophageal echocardiography confirmed the presence of a roundish 1 × 1 cm thrombus in the corner between interatrial septum and aorta. Moreover a 2 × 3 cm non-mobile thrombus was detected in the right atrial appendage (figure). The left atrial appendage emptying velocity was much reduced.

Ten days after starting anticoagulation (intravenous heparin then warfarin), repeat transoesophageal echocardiography showed the resolution of the left atrial thrombus and a slight size reduction of the right atrial appendage thrombus. A few days later the patient had syncope, followed by shock and death. Necropsy revealed a massive pulmonary embolism; the right atrial appendage thrombus was still present.

In advanced forms of cardiac amyloidosis, an impairment of atrial emptying predisposes to atrial thrombosis, even in sinus rhythm. The atrial dysfunction has been ascribed to the combination of amyloid infiltration of atrial walls and an increase of atrial afterload owing to restrictive haemodynamics. Furthermore, clotting factors might play a role in thrombogenesis of primary systemic amyloidosis.

M SANTARONE
G CORRADO
L M TAGLIAGAMBE